A detailed history of Rockefeller Capital Management L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 70,549 shares of VRTX stock, worth $28.8 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
70,549
Previous 71,161 0.86%
Holding current value
$28.8 Million
Previous $33.4 Million 1.63%
% of portfolio
0.09%
Previous 0.1%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $281,520 - $309,537
-612 Reduced 0.86%
70,549 $32.8 Million
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $502,796 - $621,478
1,280 Added 1.83%
71,161 $33.4 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $3.81 Million - $4.17 Million
9,356 Added 15.46%
69,881 $29.2 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $2.62 Million - $3.14 Million
7,635 Added 14.44%
60,525 $24.6 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $496,110 - $531,728
1,467 Added 2.85%
52,890 $18.4 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $1.79 Million - $2 Million
5,695 Added 12.45%
51,423 $18.1 Million
Q1 2023

May 17, 2023

SELL
$283.23 - $323.1 $514,345 - $586,749
-1,816 Reduced 3.82%
45,728 $14.4 Million
Q4 2022

Mar 06, 2023

SELL
$285.76 - $321.48 $68,868 - $77,476
-241 Reduced 0.5%
47,544 $13.7 Million
Q3 2022

Nov 02, 2022

BUY
$273.83 - $305.53 $1.32 Million - $1.47 Million
4,818 Added 11.21%
47,785 $13.8 Million
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $1.42 Million - $1.77 Million
6,039 Added 16.35%
42,967 $12.1 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $1.51 Million - $1.78 Million
6,807 Added 22.6%
36,928 $9.64 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $1.11 Million - $1.4 Million
6,248 Added 26.17%
30,121 $6.61 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $1.17 Million - $1.31 Million
6,477 Added 37.23%
23,873 $4.33 Million
Q2 2021

Aug 10, 2021

SELL
$187.49 - $221.1 $252,361 - $297,600
-1,346 Reduced 7.18%
17,396 $3.51 Million
Q1 2021

May 11, 2021

BUY
$207.02 - $241.31 $1.49 Million - $1.74 Million
7,191 Added 62.25%
18,742 $4.03 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $123,998 - $165,377
599 Added 5.47%
11,551 $2.73 Million
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $115,553 - $137,001
452 Added 4.3%
10,952 $2.98 Million
Q2 2020

Aug 12, 2020

BUY
$225.48 - $295.8 $514,545 - $675,015
2,282 Added 27.77%
10,500 $3.05 Million
Q1 2020

May 12, 2020

BUY
$199.77 - $247.81 $1.2 Million - $1.48 Million
5,987 Added 268.35%
8,218 $1.96 Million
Q4 2019

Feb 07, 2020

BUY
$166.71 - $223.91 $35,009 - $47,021
210 Added 10.39%
2,231 $488,000
Q3 2019

Nov 12, 2019

BUY
$166.23 - $187.09 $87,270 - $98,222
525 Added 35.09%
2,021 $342,000
Q2 2019

Aug 09, 2019

SELL
$164.61 - $190.37 $198,848 - $229,966
-1,208 Reduced 44.67%
1,496 $274,000
Q1 2019

May 10, 2019

BUY
$163.73 - $194.7 $347,435 - $413,153
2,122 Added 364.6%
2,704 $497,000
Q4 2018

Feb 12, 2019

BUY
$151.91 - $192.21 $80,816 - $102,255
532 Added 1064.0%
582 $96,000
Q2 2018

Jul 31, 2018

BUY
$145.72 - $169.96 $7,286 - $8,498
50 New
50 $8,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Rockefeller Capital Management L.P. Portfolio

Follow Rockefeller Capital Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Rockefeller Capital Management L.P. with notifications on news.